Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose IL-2 and Nivolumab in Metastatic Melanoma and Renal Cell Carcinoma
NCT03991130Phase 2Terminated
- Start
- Jul 2019
- Primary completion
- Feb 2023
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in melanoma and renal cell carcinoma (RCC). Primary endpoint: Overall Response Rate at 45 months. Started Jul 2019; status: terminated.
02
Drugs
aldesleukin
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03991130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991130.